Resources

Resources

{site_title}

Oxidant Stress as a major determinant of platelet activation in invasive breast cancer

“Breast cancer (BC) is the most common female cancer and the second leading cause of cancer-related death in women, worldwide."  Recent data have clearly demonstrated that type 2 diabetes (T2D) and obesity are among the most important risk factors for postmenopausal estrogen-dependent BC, also suggesting that oxidative stress might represent a shared mechanism for BC initiation and/or progression.

 “The results obtained showed that presurgical urinary excretion of both biomarkers was enhanced in BC patients compared to controls and was associated with patients’ estrogen receptor (ER) expression, but not HER2 status or Ki67 proliferation index. Accordingly, both urinary biomarkers were increased in patients with luminal-like BC molecular subtypes compared with triple negative or HER2-enriched tumors. "The prognostic value of 11-dehydro-TXB2 was then evaluated showing a significant correlation with BC pathological response to neoadjuvant treatment. Furthermore, among relapsing patients, those with elevated urinary biomarker levels were more likely to develop distant metastasis rather than local recurrence."

Read More

Prognostic value of urinary 11-dehydro-thromboxane B2 for mortality: A cohort study of stable coronary artery disease patients treated with aspirin

"There is a variable cardiovascular risk reduction attributable to aspirin because of individual differences in the suppression of thromboxane A2 and its downstream metabolite 11-dehydrothromboxane B2 (11dhTxB2). Our data indicates the optimal cut point for urine 11dhTxB2 is 1597.8 (pg/mg) for the risk prediction of mortality over five years in stable patients with CAD patients treated with aspirin."

Read More

Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery

"Long-term nonplatelet thromboxane generation after coronary artery bypass graft surgery is a novel risk factor for 5-year adverse outcome, including death. In contrast, nonplatelet thromboxane generation in the early postoperative period appears to be dirven predominantly by inflammation and did not independently predict long-term clinical outcome."

Read More

Relationship of PCSK9 and urinary Thromboxane Excretion to Cardiovascular Events in Patients with Atrial Fibrillation

"Soluble proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular events (CVEs) in patients who are at high cardiovascular risk. No data on the effect of PCSK9 levels in patients with atrial fibrillation (AF) are available. This study investigated the association between PCSK9 and CVEs in AF; as well as, the relationship between PCSK9 and urinary 11-dehydro-thromboxane B2 (11-dh-TxB2), a marker of platelet activation. Plasma PCSK9 levels are associated with an increased risk of CVEs in patients with AF. The direct correlation between PCSK9 and 11-dh-TxB2 suggests PCSK9 as a mechanism potentially implicated in platelet activation."

Read More

Inhibiting breast cancer by targeting the thromboxane A2 pathway

“Cyclooxygenases have been implicated in mammary tumorigenesis. We sought to identify the key prostaglandin responsible for the pro-neoplastic effect of cyclooxygenases and develop prostaglandin-targeted strategies for breast cancer chemoprevention or therapy."

“Clinically, the thromboxane A2 pathway might be associated with HER2- positive and axillary lymph node metastasis in human breast cancer. We found that the thromboxane A2 pathway was required for breast cancer cell growth, anchorage-independent growth and invasion capabilities."

Read More

Urinary 11-dehydro-thromboxane B2 and mortality in patients with stable coronary artery disease

"Urinary concentration of 11DHTXB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures."

Read More

Urinary 11-dehydro-thromboxane B2 as a predictor of acute myocardial infarction outcomes: results of leukotriene and thromboxane in myocardial infarction (LTMI) study

"Urinary 11-dehydro-thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients.”

“11-Dehydro-TXB2 predicts 1-year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance."

Read More

Urinary 11-Dehydro-Thromboxane B2: A Novel Thrombosis Risk Marker in LVAD Recipients

"Urinary 11-dehydrothromboxane B2 (UTBx) was associated with an increased risk of thrombotic events in two major clinical trials of cardiovascular disease. The utility of UTBx as a thrombotic risk marker in patients treated with a left ventricular assist device (LVAD) is unknown. In this first report the serial assessment of UTBx and measurement of UTBx at the time of adverse event occurrence in LVAD recipients, UTBx was associated with aspirin dose, bleeding and thrombotic events."

Read More

Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus

"Resistin is an adipokine that promotes inflammation and insulin resistance by targeting several cells including platelets. We hypothesised that in type 2 diabetes (T2DM), resistin may foster in vivo oxidative stress, thromboxane-dependent platelet activation and platelet-derived inflammatory proteins release, key determinants of atherothrombosis. Age and gender adjusted serum resistin levels were significantly higher in patients than in controls. HOMA and 11-dehydro-TXB2 independently predicted resistin levels."

Read More

Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men

"The exercise paradox infers that, despite the well-established cardioprotective effects of repeated episodic exercise (training), the risk of acute atherothrombotic events may  be transiently increased during and soon after an exercise bout.  However, the acute impact of different exercise modalities on platelet function has not previously been addressed.  We hypothesized that distinct modalities of exercise would have differing effects on in vivo platelet activation and reactivity to agonists which induce monocyte-platelet aggregate (MPA) formation."

Read More